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Table
SCT Diagnosis Status at SCT Preparative regimen TBI/ TLI
dose
Outcome Survival at last follow-up
(Oct 13)
1 Hurler’s Advanced disease Full prep/CD34 selected
PBSCT
- Engrafted D+10; secondary
graft failure; auto-reconstituted
Alive at 2 years/ lost to
follow-up
2 Hepatitis
Associated Aplastic
Anemia
Post liver transplant/
prolonged aplasia
Reduced intensity/
T- deplete BMT
- Engrafted D+14, secondary
graft failure; auto-reconstituted
Alive at 4 years/ lost to
follow-up
3 Hodgkin
Lymphoma
3rd relapse Reduced
intensity/ T replete BMT
TBI 2Gy Engrafted D+13; remission
D+60; relapsed D+98
Died of disease D+192
4 Therapy- Related
AML
1st remission Reduced intensity/
T- replete BMT
TBI 2Gy Engrafted D+14; remission
D+21; relapsed D+61
Died of disease 0+164
5 Therapy- Related
AML
Progressive disease/ NK
cell therapy/ 2nd SCT
NK conditioning/
T-deplete PBSCT
TBI 2Gy Engrafted D+9, remission D+2l,
MRD relapsed D+176/ DLI & NK
cell therapy
Alive, D+379
6 B Lineage ALL 2nd remission Full prep/T- deplete
PBSCT
TLI 8Gy Engrafted D+10; remission
since 0+21
Alive, D+365
7 B Lineage ALL 2nd remission Full prep/T- deplete
PBSCT
TLI 8Gy Engrafted D+10; remission
since D+21
Alive, D+365
8 Anaplastic Large
Cell Lymphoma
Progressive disease Reduced intensity/
T- deplete PBSCT
- Engrafted D+1; remission since
D+7, severe GVHD
Alive, D+200
9 Second AML Progressive disease/ NK
cell therapy/ 3rd SCT
Full prep/T- deplete
(TCRab) PBSCT
TLI 6Gy Engrafted D+10; remission
0+21: relapsed 0+60
Died of regimen-related
tonicity (encephalopathy)/
disease D+90
10 Burkitt’s lymphoma Progressive disease/ NK
cell therapy
Full prep/T- deplete
(TCRab) PBSCT
TBI 6Gy Engrafted D+8; remission D+21;
relapsed D+31/ DLI therapy
Alive, D+97
11 Early T Cell All 1st remission Full prep/T deplete
(TCRab) PESCT
TBI 6Gy Engrafted D+8; remission Died of regimen- related
tonicity (hepatic failure)
D+21
12 MDS/RAEB Evolving disease Full prep/T- deplete
(TCRab) PBSCT
TLI 6Gy Engrafted transiently; graft
failure
Alive, D+41, in 2nd SCT
13 t lineage AH 2nd remission Full prep/T deplete
(TTCRab) PBSCT
TLI 6Gy Engrafted D+10, remission
D+21
Alive, D+34
14 MDS/RAEB Graft failure/ 2nd SCT Redund intensity/
T- replete BMT
TBI 2Gy Awaiting engraftment Alive, D+13 of 2nd SCT
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(N¼4) depletion was performed in 10 SCT and CD34 positive
selection in 1. The other 3 patients received T-replete SCT
with post-transplant cyclophosphamide as per Hopkins
protocol. For the 11 T-deplete SCT, the median CD34 (x106/
kg) was 8.8 (range, 3.4-24.2) and CD3 (x104/kg) was 5 (range,
0-11). For the 3 T-replete SCT, the median TNC (x108/kg) was
2.9 (range, 2.9-4.2); CD34 (x106/kg) was 3.9 (range, 1.4-5.5)
and CD3 (x108/kg) was 0.4 (range, 0.2-2.9). For the 2 patients
with non-malignant diseases, both suffered secondary graft
failure, auto-reconstituted and survived. For the 11 patients
with high risk cancers; 6 had progressive disease at time of
SCT; 4 are surviving (1 in remission, 3 with disease) and 2
died of disease. Of the 5 patients entering SCT in remission; 3
are alive and in remission; 1 died of disease and another of
regimen-related toxicity. In 11 T-deplete SCT, viral reac-
tivations of CMV, Adenovirus, EBV, BK virus occurred in 8, 3,
3, and 2 patients, respectively. The preliminary experience of
haploidentical SCT in our small cohort of patients is
encouraging with no infective mortality and good engraft-
ment rates even for patients entering SCTwith bulky disease.
‘Graft versus leukemia/ lymphoma’ effects are evident and
may be exploited further through adoptive cell therapy in
post-transplant settings to achieve more durable remissions.270
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Standard conditioning regimes for myeloid malignancies
are TBI or Busulfan-based with Cyclophosphamide. The
reported event-free survival (EFS) is 40-60% and trans-
plant-related mortality (TRM) of 4-30%. We designed a
regime of Fludarabine, Busulfan and Melphalan (FluBuMel)
in an attempt to increase the survival rate without
increased TRM.
Methods: Retrospective review of pediatric patients with
myeloid malignancies who underwent HSCT at our institu-
tion from September 2005 to September 2010.
Results: There were 19 patients who underwent HSCT in the
time period. Median age is 5 (range, 1-20) years. There were
15 patients in CR1, 2 patients in CR2 and 2 patients not in CR.
Patients received Fludarabine (120mg/m2) + Busulfan,
weight-based dosing + Melphalan 140mg/m2 (15 patients)
decreased to 70mg/m2 (3 patients), and 1 infant with weight
adjusted dose with Cyclosporine + ATG + MTX as GVHD
prophylaxis. Average length of stay fromDay 0 to discharge is
28 (range, 17-51) days. All patients achieved neutrophil
recovery at median 14 (range, 10-46) days. All patients ach-
ieved > 95% chimerism (D+21) and 100% (D+100). Regimen-
related toxicities were CTC grade 2-3 mucositis (89%),
seizures (10%) and sinusoidal obstruction syndrome (SOS)
(15%). Decreasing the Melphalan dose did not decrease the
occurrence of mucositis and SOS in the 3 patients. Busulfan
pharmacokinetics was not measured; all patients received
phenytoin prophylaxis at therapeutic levels. The 100-day
TRM is 0%. Overall, 47% had grade 1-2 aGVHD, 21 % grade 3-4
aGVHD and 76% had cGVHD. The 2-year overall survival (OS)
Abstracts / Biol Blood Marrow Transplant 20 (2014) S165eS183 S183& EFS for the 15 patients in CR 1 are 93%, and 80% respec-
tively. Both of the patients not in CR died of disease.
Conclusion: In our limited number of patients, we found
FluBuMel to have excellent engraftment rates with very low
TRM. However, there were high occurrence of toxicities,
particularly mucositis and SOS.271
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Background: Myeloablative conditioning and AlloSCT in
childrenwith AML in CR1 is associated with a 60% event-free
survival (EFS) but may be associated with signiﬁcant acute
toxicity and late effects (Woods et al; Blood, 2001). Reduced-
intensity conditioning (RIC) and AlloSCT in children is safe,
feasible and may be associated with less adverse effects (Del
Toro/Cairo et al, BMT, 2004; Satwani/Cairo, BBMT, 2013).
Gemtuzumab ozogamicin (GO) has been demonstrated to
induce response in 30% CD33+ pediatric relapsed/refractory
AML (Sievers et al, JCO, 2001). The dose of GO is signiﬁcantly
lower when combined with chemotherapy (Aplenc, JCO,
2008).Objective: We examined the feasibility and toxicity of RIC-
AlloSCT followed by GO targeted immunotherapy in children
with CD33+ AML in CR1/CR2.
Methods: Conditioning consisted of ﬂudarabine 30mg/m2 x
6 days and busulfan 3.2-4mg/kg x 2 days  rabbit ATG 2mg/
kg x 4 days followed by AlloSCT from matched related/un-
related donors. GO was administered 55 days post-AlloSCT
in 2 doses (8 weeks apart), following a dose escalation design
(4.5, 6, 7.5 and 9 mg/m2).
Results: Thirteen patients with average risk AML received
RIC AlloSCT: median age of 14.5 years at transplant (range:
11-21); M:F:7:6; disease status at AlloSCT: 10 CR1, 3 CR2.
Eleven patients received AlloSCT from 5-6/6 HLA matched
family donors: 8 received PBSCs, 2 received BM and 1
received umbilical cord blood transplantation (UCBT). Two
patients received an unrelated graft (HLA matching 14/6 and
1 9/10) from UCBT and BM, respectively. Neutrophil
engraftment and platelet engraftment was observed in 13
patients (100%) and was achieved at a median of 14 days
(range 7-31) and 18 days (range 10-52), respectively. Three
patients received GO at dose level 1 (4.5 mg/m2/dose), 5 at
dose level 2 (6 mg/m2/dose), 3 at dose level 3 (7.5 mg/m2/
dose) and 2 at dose level 4 (9 mg/m2/dose). The ﬁrst dose of
GO was administered after 55 days post-transplant. One
patient experienced grade III transaminitis which resolved;
no grade IV transaminitis, no grade III/IV hyperbilirubinemia
or VOD. Twelve and 7 patients experienced grade 4 myeloid
toxicity and grade 4 thrombocytopenia, respectively.
Following the ﬁrst dose of GO, neutrophil and platelet re-
covery was achieved at median of 14 days (range 9-18) and
11 days (range 6-17), respectively. The second dose of GOwas
given at a median of 143 days (range: 120-209) post-trans-
plant. The probability of grade II-IV aGVHD was 15.4%.
Probability of overall survival following RIC-AlloSCT and GO
consolidation at 1 and 3 years was 83.3% and 65.6%,
respectively. There have been no DLTs observed in this cohort
during this time period.
Conclusion: This preliminary data demonstrates that RIC
followed by AlloSCT and consolidationwith GO appears to be
safe in children with CD33+ AML in CR1/CR2. A larger cohort
with longer follow-up is required to determine the long-term
clinical signiﬁcance.
